Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Amyloid Fibrils03:03

Amyloid Fibrils

9.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

579
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
579
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
Neural Regulation01:37

Neural Regulation

39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Dementia01:30

Dementia

121
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.

JAMA·2026
Same author

Postmortem brain MRI reveals differential associations of subcortical and limbic volumes with cortical thinning and neurodegenerative pathologies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Allogeneic hematopoietic cell transplantation with reduced-toxicity conditioning for X-linked hyper-IgM syndrome.

International journal of hematology·2026
Same author

Annexin A11 and TDP-43: core players in neurodegeneration.

Acta neuropathologica·2026
Same author

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.

Acta neuropathologica·2026
Same author

Characterizing the MRI signature of hippocampal sclerosis of aging.

Alzheimer's research & therapy·2026

Related Experiment Video

Updated: Jul 13, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K

Neurodegenerative Disease Tauopathies.

Benjamin C Creekmore1, Ryohei Watanabe1, Edward B Lee1

  • 1Translational Neuropathology Research Laboratory, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA;

Annual Review of Pathology
|October 13, 2023
PubMed
Summary

Tauopathies are neurodegenerative diseases caused by abnormal tau protein aggregates. This review explores how these tau aggregates spread between neurons, leading to cell death and varied symptoms like dementia.

Keywords:
ADAlzheimer's diseaseFTLDMAPTcryo-EMcryogenic electron microscopyfrontotemporal lobar degenerationmicrotubule-associated protein tauproteostasistauopathy

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.0K
An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

6.0K

Related Experiment Videos

Last Updated: Jul 13, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.4K
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.0K
An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons
05:51

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

6.0K

Area of Science:

  • Neuroscience
  • Pathology
  • Genetics

Background:

  • Tauopathies encompass progressive neurodegenerative conditions.
  • Characterized by abnormal tau protein inclusions in the central nervous system.
  • Pathologic tau aggregates correlate with neuronal death and diverse clinical presentations.

Purpose of the Study:

  • To review the clinicopathologic features of tauopathies.
  • To highlight advances in understanding tau aggregate propagation.
  • To link tau spread to molecular and cellular mechanisms.

Main Methods:

  • Literature review of tauopathies.
  • Analysis of mechanisms of tau aggregate cell-to-cell spread.
  • Examination of factors influencing tau pathology.

Main Results:

  • Tau aggregates spread through interconnected neuronal pathways.
  • Cell-to-cell propagation is influenced by posttranslational modifications.
  • Tau fibril structure and protein quality control breakdown contribute to spread.

Conclusions:

  • Tauopathies are complex diseases driven by tau pathology spread.
  • Understanding propagation mechanisms is key to therapeutic development.
  • Posttranslational modifications and protein quality control are critical factors.